Objective To inform the development of an evidence synthesis taxonomy, we aimed to identify and examine all classification ...

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three phase 3 ...